Gsk (GLAXF) Dividends Paid - Common (2009 - 2026)
Gsk (GLAXF) recorded quarterly Dividends Paid - Common of -$866.9 million in Q1 2026, down 66.68% quarter-over-quarter from -$520.1 million in Q4 2025, and down 12.46% on a YoY basis from -$990.3 million in Q1 2025.
Gsk (GLAXF) Dividends Paid - Common (2009 - 2026) Analysis & Trends
Gsk's Dividends Paid - Common history runs 18 years deep, the most recent figure standing at -$866.9 million for Q1 2026.
- In Q1 2026, Dividends Paid - Common fell 12.46% year-over-year to -$866.9 million; the TTM figure through Mar 2026 stood at -$1.7 billion (down 42.76% YoY), while the FY2025 annual figure was $3.4 billion, up 8.21% from the prior year.
- Dividends Paid - Common was -$866.9 million for Q1 2026 at Gsk, down from -$520.1 million in the prior quarter.
- In the past five years, Dividends Paid - Common ranged from a high of $6.0 billion in Q4 2022 to a low of -$1.3 billion in Q1 2022.
- Historically, Dividends Paid - Common has averaged -$5.1 million across 5 years, with a median of -$167.9 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Dividends Paid - Common jumped 1976.03% in 2022, then plunged 216.57% in 2025.
- A 5-year view of Dividends Paid - Common shows it stood at $6.0 billion in 2022, then plunged by 101.6% to -$96.8 million in 2023, then tumbled by 69.7% to -$164.3 million in 2024, then slumped by 216.57% to -$520.1 million in 2025, then tumbled by 66.68% to -$866.9 million in 2026.
- The last three Dividends Paid - Common figures came in at -$866.9 million (Q1 2026), -$520.1 million (Q4 2025), and -$133.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends Paid - Common (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -866.88 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.55 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 3.13 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 3.09 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 2.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.36 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.04 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.45 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.28 Bn |
| 10 | Gsk | - | - | 7.76 Bn | -866.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -866.88 Mn |
| Mar 31, 2026 | -866.88 Mn |
| Dec 31, 2025 | -520.09 Mn |
| Dec 31, 2025 | -520.09 Mn |
| Sep 30, 2025 | -133.59 Mn |
| Sep 30, 2025 | -133.59 Mn |
| Jun 30, 2025 | -162.75 Mn |
| Jun 30, 2025 | -162.75 Mn |
| Mar 31, 2025 | -770.81 Mn |
| Mar 31, 2025 | -770.81 Mn |
| Dec 31, 2024 | -164.29 Mn |
| Dec 31, 2024 | -164.29 Mn |
| Sep 30, 2024 | -103.94 Mn |
| Sep 30, 2024 | -103.94 Mn |
| Jun 30, 2024 | -140.11 Mn |
| Jun 30, 2024 | -140.11 Mn |
| Mar 31, 2024 | -720.52 Mn |
| Mar 31, 2024 | -720.52 Mn |
| Dec 31, 2023 | -96.81 Mn |
| Dec 31, 2023 | -96.81 Mn |